No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
VKTX240726C57000
- 3.10
- -0.35-10.14%
15min DelayClose Jul 19 16:00 ET
3.65High2.63Low
2.63Open3.45Pre Close38 Volume97 Open Interest57.00Strike Price12.16KTurnover247.94%IV18.07%PremiumJul 26, 2024Expiry Date0.00Intrinsic Value100Multiplier4DDays to Expiry3.10Extrinsic Value100Contract SizeAmericanOptions Type0.3968Delta0.0270Gamma14.75Leverage Ratio-0.6221Theta0.0021Rho5.85Eff Leverage0.0222Vega
Intraday
- 5D
- Daily
No Data
News
The trend of weight loss drug sector in US stock market is diverging. Novo Nordisk (NVO.US) and Eli Lilly and Co (LLY.US) face challenges to their duopoly.
As more and more pharmaceutical companies enter the lucrative weight loss drug market to get a share of the pie, the increasing competition is making investors worried about the duopoly position of Novo Nordisk and Eli Lilly and Co in this market.
Viking Therapeutics, Inc. (VKTX) Gains As Market Dips: What You Should Know
Should Viking (VKTX) Stock Be in Your Portfolio Pre-Q2 Earnings?
The biotech firm’s performance has been mixed over the trailing four quarters.
Is Viking Therapeutics a Millionaire-Maker?
EXCLUSIVE: Weight-Loss Duopoly Breaks As Eli Lilly, Novo Plummet; 'Market Won't Be Dominated By Just 2 Players'
GLP-1 market leaders Eli Lilly and Company (NYSE:LLY) and Novo Nordisk A/S (NYSE:NVO) faced a significant selloff on Thursday, as new weight-loss drugs from rival pharmaceutical companies began threatening the dominance of their flagship products, Zepbound and Wegovy.
Why the Market Dipped But Viking Therapeutics, Inc. (VKTX) Gained Today
Comments
$ROCHE HOLDING AG(RHHBY.US$
📣 Roche News Snippet:
» CT-996 led to significant weight loss (-7.3%) after 4 weeks 🆚 placebo (-1.2%)
» data supports once-daily oral dosing regimen
» Safety profile was similar to other GLP-1 drugs; no unexpected safety issues observed
Did you see today's sell-off? 🔴
$Eli Lilly and Co(LLY.US$ $Novo-Nordisk A/S(NVO.US$ $Structure Therapeutics(GPCR.US$ $Viking Therapeutics(VKTX.US$ $Lipocine(LPCN.US$
📣 Roche News Snippet:
» CT-996 led to significant weight loss (-7.3%) after 4 weeks 🆚 placebo (-1.2%)
» data supports once-daily oral dosing regimen
» Safety profile was similar to other GLP-1 drugs; no unexpected safety issues observed
Did you see today's sell-off? 🔴
$Eli Lilly and Co(LLY.US$ $Novo-Nordisk A/S(NVO.US$ $Structure Therapeutics(GPCR.US$ $Viking Therapeutics(VKTX.US$ $Lipocine(LPCN.US$
5
$Viking Therapeutics(VKTX.US$
sad indeed, all this winning makes me tired 😫
$Viking Therapeutics(VKTX.US$
sad indeed, all this winning makes me tired 😫
$Viking Therapeutics(VKTX.US$
Unsupported module.
Please view on mobile devices.
3
im bored. It's late. I might as well update my last post and see how i did.
Well, that went swell 😁 that's my post from the 10th. It received 23k views with 1 cry face and 1 sell comment (2 broke readers💔).
You can read it if you haven't. Here is how I did.
early in the day
And here is how we closed
$iShares Russell 2000 ETF(IWM.US$ $iShares Russell 2000 ETF(IWM.US$
Pow Pow 💥
$Trump Media & Technology(DJT.US$
$GameStop(GME.US$
this is going to go, it's called buil...
Well, that went swell 😁 that's my post from the 10th. It received 23k views with 1 cry face and 1 sell comment (2 broke readers💔).
You can read it if you haven't. Here is how I did.
early in the day
And here is how we closed
$iShares Russell 2000 ETF(IWM.US$ $iShares Russell 2000 ETF(IWM.US$
Pow Pow 💥
$Trump Media & Technology(DJT.US$
$GameStop(GME.US$
this is going to go, it's called buil...
+5
20
$Viking Therapeutics(VKTX.US$ told you guys this goes green, weak hands just got cheated by market makers.
$Viking Therapeutics (VKTX.US)$ competition is good, Pfizer joining the game means that vktx is on right path, means other larger players will look at vktx for acquisition in order to compete with pfizer
4
Read more